Please use this identifier to cite or link to this item: https://doi.org/10.1080/21645515.2015.1126012
Title: Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naive vaccinees
Authors: Velumani, Sumathy
Toh, Ying Xiu
Balasingam, Shobana
Archuleta, Sophia 
Leo, Yee Sin 
Gan, Victor C
Thein, Tun Linn
Wilder-Smith, Annelies 
Fink, Katja
Keywords: Science & Technology
Life Sciences & Biomedicine
Biotechnology & Applied Microbiology
Immunology
antibodies
dengue
immune memory
long-term
memory B cells
vaccine
B-CELL RESPONSES
VIRUS-INFECTION
PROTECTIVE EFFICACY
TIME-INTERVAL
MEMORY
HUMANS
RECOMBINANT
MACROPHAGES
SEROTYPES
CHILDREN
Issue Date: 1-Jan-2016
Publisher: TAYLOR & FRANCIS INC
Citation: Velumani, Sumathy, Toh, Ying Xiu, Balasingam, Shobana, Archuleta, Sophia, Leo, Yee Sin, Gan, Victor C, Thein, Tun Linn, Wilder-Smith, Annelies, Fink, Katja (2016-01-01). Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naive vaccinees. HUMAN VACCINES & IMMUNOTHERAPEUTICS 12 (5) : 1265-1273. ScholarBank@NUS Repository. https://doi.org/10.1080/21645515.2015.1126012
Abstract: Globally, dengue virus (DENV) is one of the most widespread vector-borne viruses. Dengue disease affects populations in endemic areas and, increasingly, tourists who travel to these countries, but there is currently no approved vaccine for dengue. A phase 3 efficacy trial with Sanofi-Pasteur's recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) conducted in South East Asia showed an overall efficacy of 56% against virologically confirmed dengue infections of any severity and any of the 4 serotypes, but the long-term protection of the vaccine has yet to be demonstrated. To address longevity of antibody titers and B cell memory, we recalled study participants from an earlier CYD immunogenicity study (Phase 2) conducted in Singapore that enrolled healthy volunteers in the year 2009. Depending on the age group, 57–84% of the participants initially generated a neutralizing antibody titer ≥ 10 to all 4 DENV serotypes 28 d after the third and final dose. We observed very low antibody titers in blood samples collected from 23 vaccinees 5 y after the first dose, particularly titers of antibodies binding to virus particles compared with those binding to recombinant E protein. The in vivo efficacy of plasma antibodies against DENV-2 challenge was also tested in a mouse model, which found that only 2 out of 23 samples were able to reduce viremia. Although the sample size is too small for general conclusions, dengue immune memory after vaccination with CYD-TDV appears relatively low.
Source Title: HUMAN VACCINES & IMMUNOTHERAPEUTICS
URI: https://scholarbank.nus.edu.sg/handle/10635/228196
ISSN: 21645515
2164554X
DOI: 10.1080/21645515.2015.1126012
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
khvi-12-05-1126012.pdfPublished version1.11 MBAdobe PDF

CLOSED

Published

SCOPUSTM   
Citations

16
checked on Sep 23, 2022

Page view(s)

24
checked on Sep 22, 2022

Download(s)

2
checked on Sep 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.